Finance

Lists
KOO:LON
Kooth PLC
GBX 187,20
+0,65%
(+1,20) 1D
2 āš•.āšĨ., 16 āŧ‚āšĄāš‡ 30 āš™āšēāš—āšĩ 00 āš§āšīāš™āšēāš—āšĩ GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for KOO...
Open
GBX 186,00
High
GBX 190,00
Low
GBX 180,00
Mkt. cap
68,11 āšĨāŧ‰āšēāš™
Avg. vol.
222,22Â āšžāšąāš™
Volume
20,03Â āšžāšąāš™
P/E ratio
12,80
52-wk high
GBX 203,00
52-wk low
GBX 96,00
EPS
GBX 0,15
Shares outstanding
36,39 āšĨāŧ‰āšēāš™
No. of employees
554
Open
GBX 186,00
High
GBX 190,00
Low
GBX 180,00
Mkt. cap
68,11 āšĨāŧ‰āšēāš™
Avg. vol.
222,22Â āšžāšąāš™
Volume
20,03Â āšžāšąāš™
P/E ratio
12,80
52-wk high
GBX 203,00
52-wk low
GBX 96,00
EPS
GBX 0,15
Shares outstanding
36,39 āšĨāŧ‰āšēāš™
No. of employees
554
News stories
From web sources and news partners
Intellia Therapeutics
Intellia Therapeutics
·
30 āš™āšēāš—āšĩāšāŧˆāš­āš™
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance UK
Yahoo Finance UK
·
31 āš™āšēāš—āšĩāšāŧˆāš­āš™
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
GlobeNewswire
·
27 āš™āšēāš—āšĩāšāŧˆāš­āš™
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CNBC
CNBC
·
2 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
Friday's rally in the S&P 500 might not be enough, but Linde is out of this world
About Kooth PLC
CEOTim Barker
Employees554
Founded2001
Headquarters-
SectorHealth care provider
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
āš.āš. 2025
āš—.āš§. 2025
āšĄ.āš™. 2026
āšĄāšī.āš–. 2026
Revenue
15,60 āšĨāŧ‰āšēāš™
15,60 āšĨāŧ‰āšēāš™
15,41 āšĨāŧ‰āšēāš™
15,41 āšĨāŧ‰āšēāš™
Cost of goods sold
2,10 āšĨāŧ‰āšēāš™
2,10 āšĨāŧ‰āšēāš™
2,25 āšĨāŧ‰āšēāš™
2,25 āšĨāŧ‰āšēāš™
Cost of revenue
2,10 āšĨāŧ‰āšēāš™
2,10 āšĨāŧ‰āšēāš™
2,25 āšĨāŧ‰āšēāš™
2,25 āšĨāŧ‰āšēāš™
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,39 āšĨāŧ‰āšēāš™
9,39 āšĨāŧ‰āšēāš™
10,64 āšĨāŧ‰āšēāš™
10,64 āšĨāŧ‰āšēāš™
Operating expense
10,96 āšĨāŧ‰āšēāš™
10,96 āšĨāŧ‰āšēāš™
12,14 āšĨāŧ‰āšēāš™
12,14 āšĨāŧ‰āšēāš™
Total operating expenses
13,05 āšĨāŧ‰āšēāš™
13,05 āšĨāŧ‰āšēāš™
14,39 āšĨāŧ‰āšēāš™
14,39 āšĨāŧ‰āšēāš™
Operating income
2,55 āšĨāŧ‰āšēāš™
2,55 āšĨāŧ‰āšēāš™
1,02 āšĨāŧ‰āšēāš™
1,02 āšĨāŧ‰āšēāš™
Other non operating income
130,50Â āšžāšąāš™
130,50Â āšžāšąāš™
80,50Â āšžāšąāš™
80,50Â āšžāšąāš™
EBT including unusual items
3,05 āšĨāŧ‰āšēāš™
3,05 āšĨāŧ‰āšēāš™
1,32 āšĨāŧ‰āšēāš™
1,32 āšĨāŧ‰āšēāš™
EBT excluding unusual items
3,05 āšĨāŧ‰āšēāš™
3,05 āšĨāŧ‰āšēāš™
1,32 āšĨāŧ‰āšēāš™
1,32 āšĨāŧ‰āšēāš™
Income tax expense
1,12 āšĨāŧ‰āšēāš™
1,12 āšĨāŧ‰āšēāš™
330,50Â āšžāšąāš™
330,50Â āšžāšąāš™
Effective tax rate
36,62%
36,62%
24,98%
24,98%
Other operating expenses
-
-
-
-
Net income
1,93 āšĨāŧ‰āšēāš™
1,93 āšĨāŧ‰āšēāš™
992,50Â āšžāšąāš™
992,50Â āšžāšąāš™
Net profit margin
12,38%
12,38%
6,44%
6,44%
Earnings per share
-
-
-
-
Interest and investment income
187,00Â āšžāšąāš™
187,00Â āšžāšąāš™
259,00Â āšžāšąāš™
259,00Â āšžāšąāš™
Interest expense
-
-
-
-
Net interest expenses
187,00Â āšžāšąāš™
187,00Â āšžāšąāš™
259,00Â āšžāšąāš™
259,00Â āšžāšąāš™
Depreciation and amortization charges
1,56 āšĨāŧ‰āšēāš™
1,56 āšĨāŧ‰āšēāš™
1,50 āšĨāŧ‰āšēāš™
1,50 āšĨāŧ‰āšēāš™
EBITDA
2,58 āšĨāŧ‰āšēāš™
2,58 āšĨāŧ‰āšēāš™
1,06 āšĨāŧ‰āšēāš™
1,06 āšĨāŧ‰āšēāš™
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
āŧāš­āšąāššāš‚āš­āš‡ Google